GOVX vs. ALLK, DERM, PYRGF, CTOR, BGM, EPIX, ASRT, THTX, AADI, and ALTS
Should you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Allakos (ALLK), Journey Medical (DERM), PyroGenesis Canada (PYRGF), Citius Oncology (CTOR), Qilian International Holding Group (BGM), ESSA Pharma (EPIX), Assertio (ASRT), Theratechnologies (THTX), Aadi Bioscience (AADI), and Janone (ALTS). These companies are all part of the "pharmaceutical products" industry.
GeoVax Labs vs.
Allakos (NASDAQ:ALLK) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.
In the previous week, GeoVax Labs had 2 more articles in the media than Allakos. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for Allakos. Allakos' average media sentiment score of 0.87 beat GeoVax Labs' score of 0.53 indicating that Allakos is being referred to more favorably in the media.
GeoVax Labs has higher revenue and earnings than Allakos.
84.6% of Allakos shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 16.1% of Allakos shares are held by insiders. Comparatively, 5.7% of GeoVax Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Allakos received 160 more outperform votes than GeoVax Labs when rated by MarketBeat users. However, 95.83% of users gave GeoVax Labs an outperform vote while only 59.22% of users gave Allakos an outperform vote.
Allakos currently has a consensus price target of $2.00, indicating a potential upside of 133.78%. GeoVax Labs has a consensus price target of $14.20, indicating a potential upside of 539.64%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Allakos.
Allakos' return on equity of -140.87% beat GeoVax Labs' return on equity.
Allakos has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.29, meaning that its share price is 229% more volatile than the S&P 500.
Summary
GeoVax Labs beats Allakos on 9 of the 15 factors compared between the two stocks.
Get GeoVax Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GeoVax Labs Competitors List
Related Companies and Tools
This page (NASDAQ:GOVX) was last updated on 1/20/2025 by MarketBeat.com Staff
